531015 VENMAX

Venmax Drugs & Pharmaceuticals Share Price

 

 

Start SIP in VENMAX

Start SIP
Venmax Drugs & Pharmaceuticals live price: ₹23.85. It opened at ₹23 vs previous close ₹23; intraday high/low: ₹25/₹21. The 50 & 200 DMA stand at ₹25.95/₹25.24.

Venmax Drugs & Pharmaceuticals Performance

  • Low
  • ₹21
  • High
  • ₹25
  • 52 Week Low
  • ₹19
  • 52 Week High
  • ₹37
  • Open Price₹23
  • Previous Close₹23
  • Volume1,492
  • 50 DMA₹25.95
  • 100 DMA₹26.23
  • 200 DMA₹25.24

Investment Returns

  • Over 1 Month -15.43%
  • Over 3 Month -9.45%
  • Over 6 Month -0.62%
  • Over 1 Year + 6.57%

Smart Investing Starts Here Start SIP with Venmax Drugs & Pharmaceuticals for Steady Growth!

Invest Now

Venmax Drugs & Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 14.3
  • PEG Ratio
  • 0.1
  • Market Cap Cr
  • 13
  • P/B Ratio
  • 2.1
  • Average True Range
  • 3.89
  • EPS
  • -
  • Dividend Yield
  • 0
  • MACD Signal
  • -0.3
  • RSI
  • 40.64
  • MFI
  • 19.53

Venmax Drugs & Pharmaceuticals Financials

Venmax Drugs & Pharmaceuticals Technicals

EMA & SMA

Current Price
₹23.85
+ 0.74 (3.2%)
pointer
  • Bearish Moving Average 16
  • Bullish Moving Average 0
  • 20 Day
  • ₹25.36
  • 50 Day
  • ₹25.95
  • 100 Day
  • ₹26.23
  • 200 Day
  • ₹25.24

Resistance and Support

23.25 Pivot Speed
  • R3 30.00
  • R2 27.55
  • R1 25.70
  • S1 21.40
  • S2 18.95
  • S3 17.10

Ratings

Master Rating

EPS Strenth

N/A

Price Strength

Buyer Demand

Group Rank

Venmax Dg.And Pharms. has an operating revenue of Rs. 4.41 Cr. on a trailing 12-month basis. An annual revenue growth of 830% is outstanding, Pre-tax margin of -2% needs improvement, ROE of -0% is poor and needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. From an O'Neil Methodology perspective, the stock has an EPS Rank of 0 which is a POOR score indicating inconsistency in earnings, a RS Rating of 59 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 58 indicates it belongs to a fair industry group of Medical-Diversified and a Master Score of D is close to being the worst. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment. Please note that this is a thinly traded stock.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Venmax Drugs & Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-02-07 Quarterly Results
2025-11-12 Quarterly Results
2025-09-02 Amalgamation & A.G.M.
2025-08-16 Others Inter alia, to consider and approve 1. Allotment of Equity Shares pursuant to conversion of Convertible Equity Share Warrants.
2025-07-23 Quarterly Results

Venmax Drugs & Pharmaceuticals F&O

Venmax Drugs & Pharmaceuticals Shareholding Pattern

15.14%
0%
64.25%
20.61%

About Venmax Drugs & Pharmaceuticals

  • NSE Symbol
  • VENMAX
  • BSE Symbol
  • 531015
  • ISIN
  • INE154G01022

Similar Stocks to Venmax Drugs & Pharmaceuticals

Venmax Drugs & Pharmaceuticals FAQs

Venmax Drugs & Pharmaceuticals share price is ₹23 As on 10 March, 2026 | 06:36

The Market Cap of Venmax Drugs & Pharmaceuticals is ₹12.5 Cr As on 10 March, 2026 | 06:36

The P/E ratio of Venmax Drugs & Pharmaceuticals is 14.3 As on 10 March, 2026 | 06:36

The PB ratio of Venmax Drugs & Pharmaceuticals is 2.1 As on 10 March, 2026 | 06:36

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23